Ignite Creation Date:
2025-12-25 @ 2:04 AM
Ignite Modification Date:
2026-02-09 @ 3:10 PM
Study NCT ID:
NCT00742560
Status:
COMPLETED
Last Update Posted:
2018-01-10
First Post:
2008-08-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
Sponsor:
AbbVie (prior sponsor, Abbott)
Organization: